🇺🇸 English 🇯🇵 日本語 🇻🇳 Tiếng Việt 🇨🇳 简体中文

Published : 2026.11.02 (Mon)

Add as Google preferred source Log in Sign up Send a Tip About Us

Breaking

Home › Columns

Columns

( 3 articles )

All

Strategic design is as vital as funding for early startup growth

Jeong Ji-won of J&P Medi Partners argues that early-stage startups require strategic planning and effective accelerating programs to navigate the "Valley of Death" and successfully transition from technology to business.

Strategic design is as vital as funding for early startup growth

What Investors Should Look for in Animal Testing Alternatives

J&P Medi Partners says investors should assess whether NAMs provide useful information for development decisions, meet customer needs and can support repeatable services. Its portfolio company OrganoPlus is developing human-based nonclinical validation platforms and plans to build a data production system.

What Investors Should Look for in Animal Testing Alternatives

[J&P Medi Partners Column] Investment is Not the Only Thing Early Healthcare Startups Need

The article argues that for early-stage healthcare startups, securing investment is insufficient if they lack a structured path to bridge the gap between technology and market commercialization. It emphasizes that successful growth depends on designing milestones that lead to actual purchasing decisions and transforming PoC (Proof of Concept) results into business contracts.

[J&P Medi Partners Column] Investment is Not the Only Thing Early Healthcare Startups Need

Strategic design is as vital as funding for early startup growth

정지원 2026.10.15

What Investors Should Look for in Animal Testing Alternatives

전용훈 2026.09.21

[J&P Medi Partners Column] Investment is Not the Only Thing Early Healthcare Startups Need

Strategic design is as vital as funding for early startup growth

Strategic design is as vital as funding for early startup growth

Jeong Ji-won of J&P Medi Partners argues that early-stage startups require strategic planning and effective accelerating programs to navigate the "Valley of Death" and successfully transition from technology to business.

What Investors Should Look for in Animal Testing Alternatives

What Investors Should Look for in Animal Testing Alternatives

J&P Medi Partners says investors should assess whether NAMs provide useful information for development decisions, meet customer needs and can support repeatable services. Its portfolio company OrganoPlus is developing human-based nonclinical validation platforms and plans to build a data production system.

[J&P Medi Partners Column] Investment is Not the Only Thing Early Healthcare Startups Need

[J&P Medi Partners Column] Investment is Not the Only Thing Early Healthcare Startups Need

The article argues that for early-stage healthcare startups, securing investment is insufficient if they lack a structured path to bridge the gap between technology and market commercialization. It emphasizes that successful growth depends on designing milestones that lead to actual purchasing decisions and transforming PoC (Proof of Concept) results into business contracts.